Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Amir Reichman M.B.A., M.Sc. | CEO & Director | 562k | -- | 1977 |
| Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA | Chief Financial Officer | 171k | -- | 1970 |
| Mr. Elad Mark B.Sc., Eng., M.B.A. | Chief Operating Officer | 235k | -- | 1983 |
| Dr. Dalit Weinstein Fischer Ph.D. | Chief Technology Officer | 214k | -- | 1971 |
| Dr. Tamar Ben-Yedidia Ph.D. | Chief Scientist | 254k | -- | 1964 |
| Merav Kamensky | Head of Quality Control | -- | -- | -- |
| Dr. Naama Adi Hen | Head of Quality Asurance | -- | -- | -- |
| Ms. Alona Tal | Head of Business Administration | -- | -- | -- |
Scinai Immunotherapeutics Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 31
Description
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
March 11, 2025 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission